World
Pharmac to fund two medicine combinations for chronic lymphocytic leukaemia
April 9, 2026
Radio New Zealand
Scroll
From May 1, people with chronic lymphocytic leukaemia will be able to access combination treatments of venetoclax with either ibrutinib or obinutuzumab.
Radio New Zealand
Coverage and analysis from New Zealand. All insights are generated by our AI narrative analysis engine.
New Zealand
Bias: lean left